The estimated Net Worth of Nir Yacov Barzilai is at least $2.25 Million dollars as of 1 November 2021. Nir Barzilai owns over 13,889 units of CohBar Inc stock worth over $2,182,424 and over the last 4 years he sold CWBR stock worth over $0. In addition, he makes $64,125 as Independent Director at CohBar Inc.
Nir has made over 1 trades of the CohBar Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 13,889 units of CWBR stock worth $5,972 on 1 November 2021.
The largest trade he's ever made was buying 13,889 units of CohBar Inc stock on 1 November 2021 worth over $5,972. On average, Nir trades about 6,945 units every 0 days since 2021. As of 1 November 2021 he still owns at least 5,075,405 units of CohBar Inc stock.
You can see the complete history of Nir Barzilai stock trades at the bottom of the page.
Dr. Nir Yacov Barzilai serves as Independent Director of the Company. He co-founded our Company in 2007 and has served as a member of our board of directors since our conversion to a Delaware corporation in 2009. Dr. Barzilai is the director of the Institute for Aging Research at the Albert Einstein College of Medicine of Yeshiva University, where he also holds the Ingeborg and Ira Leon Rennert Chair of Aging Research, is a professor in the Departments of Medicine and Genetics and a member of the Diabetes Research Center. Dr. Barzilai is also director of the Paul F. Glenn Center for the Biology of Human Aging Research and of the National Institutes of Health’s (NIH) Nathan Shock Centers of Excellence in the Basic Biology of Aging. Dr. Barzilai has received numerous awards, including the Beeson Fellow for Aging Research, the Ellison Medical Foundation Senior Scholar in Aging Award, the Paul F. Glenn Foundation Award, the NIA Nathan Shock Award, the 2010 Irving S. Wright Award of Distinction in Aging Research and the AFAR Wright Award. Dr. Barzilai’s leadership in gerontology research and his experience overseeing numerous research programs related to diseases of aging and mitochondrial biology makes him an important contributor to our board of directors.
As the Independent Director of CohBar Inc, the total compensation of Nir Barzilai at CohBar Inc is $64,125. There are 10 executives at CohBar Inc getting paid more, with Steven Engle having the highest compensation of $2,410,850.
Nir Barzilai is 64, he's been the Independent Director of CohBar Inc since 2018. There are 6 older and 7 younger executives at CohBar Inc. The oldest executive at CohBar Inc is Albion Fitzgerald, 71, who is the Independent Chairman of the Board.
Nir's mailing address filed with the SEC is C/O COHBAR, INC., 1455 ADAMS DRIVE, SUITE 2050, MENLO PARK, CA, 94025.
Over the last 7 years, insiders at CohBar Inc have traded over $0 worth of CohBar Inc stock and bought 586,523 units worth $136,480 . The most active insiders traders include Misha Petkevich, Kenneth C Cundy, and Jon Leland Stern. On average, CohBar Inc executives and independent directors trade stock every 22 days with the average trade being worth of $9,727. The most recent stock trade was executed by David Greenwood on 1 November 2021, trading 20,000 units of CWBR stock currently worth $8,600.
cohbar (otcqx: cwbr and tsxv: cob.u) is the leader in the research and development of mitochondria-based therapeutics (mbts), an emerging class of drugs for the treatment of diseases associated with aging. mbts originate from the discovery of a novel group of peptides within the genome of mitochondria, the powerhouses of the cell. this groundbreaking discovery was made by our founders, world leaders in the biology of aging, metabolism and mitochondrial genomics. mbts offer the potential to address a broad range of diseases such as type 2 diabetes, cancer, atherosclerosis and neurodegenerative disorders.
CohBar Inc executives and other stock owners filed with the SEC include: